Albany, NY, Jan. 23, 2018 -- As per estimates of a TMR report, the global antacids market will expand at CAGR of 3.7% for the forecast period between 2017 and 2025, for the market to be worth US$18.7 bn by 2025 end. Based on drug class, proton pump inhibitors held the leading share in the market in 2016. By distribution channel, others that constitutes online drug store and online pharmacy led the market in 2016. Europe held supremacy among other key regional markets in 2016 because of rising incidence of gastro esophageal reflux diseases.
View Report Preview at https://www.transparencymarketresearch.com/antacids-market.html
Rising Geriatric Population Pool Suffering from Gastroesophageal Reflux Diseases stokes Growth
Considering factors such as changing food habits and rising geriatric population globally, the demand for antacids is on a surge. According to the Asian Development Bank, the population that is 60 years and above is projected to touch 923 million by 2050 in Asia. This population that is more likely to suffer from gastroesophageal reflux diseases and peptic ulcers will display substantial demand for antacids in the upcoming years. Some countries in Asia Pacific, such as Japan recorded leading percentage of individuals above the age of 65 years globally in 2014. This is further acting in favor of Asia Pacific antacids market.
Further, increasing incidence of heartburn, gastro esophageal reflux diseases, and acidity along with changing dietary habits are some other key factors behind the growth of antacids market. For instance, as per a study published in Gut (BMJ journal), the percentage of population suffering from gastroesophageal reflux diseases in Europe ranges from 8.8% to 25.9%. This accounts for substantial demand for antacids in the region, with countries in Northern Europe surpassing the demand for antacids over countries in Southern Europe.
Request to View Sample of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=32864
The common practice of self-medication for occasionally occurring heartburn and acidity and easy availability of over the counter drugs for antacids is also stoking the growth of antacids market. Antacids help suppress the stomach acid either by inhibiting acid production or by neutralizing it.
Risk of Side Effects Challenges Growth
On the downside, the global antacids market is facing growth challenges as well. Serious side effects associated with prolong use of proton pump inhibitors and availability of generic drugs in developing and underdeveloped markets is impeding the market’s expansion in these regions. Excessive reliance on over-the-counter drugs is also providing headwinds to this market’s growth.
Download PDF Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=32864
The worldwide antacids market is a choc-o-bloc with large companies that hold prominence due to their product offerings and presence across geographies, observes Transparency Market Research (TMR). R&D initiatives for the introduction of novel therapies, improving efficacy of existing drugs are the focus of key players in this market to gain competitive advantage. These players are also seeking strategic partnerships and business alliances to strengthen their research expertise as well as to up their business competencies.
Prominent names in the global antacids market include AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, Pfizer Inc., Reckitt Benckiser Group plc, Sun Pharmaceuticals Ltd., Valeant Pharmaceuticals International Inc., Bayer AG, Dr. Reddy’s Laboratories Ltd., Johnson & Johnson, Procter & Gamble, Sanofi, and Takeda Pharmaceutical Company Ltd.
Buy Antacids Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=32864<ype=S
About TMR
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Contact
Nachiket Ghumare
Transparency Market Research
State Tower
90 State Street,
Suite 700,
Albany, NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com
Research Blog: http://theglobalhealthnews.com/


Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Samsung Electronics Shares Jump on HBM4 Mass Production Report
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Washington Post Publisher Will Lewis Steps Down After Layoffs 



